Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

CTP-543 is generally safe for treating alopecia areata.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

This case study reports a cutaneous adverse drug reaction in a dog caused by prolonged topical exposure to benzyl benzoate, leading to irritant contact dermatitis, but healing occurred within three weeks after changing treatment.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

This review discusses both psychiatric and medical treatments for adolescent eating disorders and highlights the need for further research, especially regarding the effectiveness of psychotropic medications in this population.

This study identified a nonfunctional Itpr3 gene in BTBR mice, attributed to a 12-bp deletion, which likely causes their simultaneous hair loss and taste perception deficits.

This article discusses the newly approved drug dutasteride for managing benign prostatic hyperplasia, but reports no new research findings; the authors advise obtaining complete information before prescribing.

This review examines recent advancements in analytical techniques used to quantify dutasteride, a medication for enlarged prostate, in various biological samples and its commercial forms, emphasizing methods such as HPTLC, GC-MS, and HPLC.

This paper highlights the emerging trend of treating androgenic alopecia with botulinum toxin, despite insufficient scientific evidence supporting its effectiveness.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This review discusses the use of baricitinib in dermatology, emphasizing its effectiveness in treating certain dermatoses, while highlighting the need for awareness of its potential side effects and calling for more long-term safety data.

Botulinum toxin injections can reduce hair loss and stimulate new hair growth in some men with male pattern baldness.

This article discusses challenges primary care physicians face in diagnosing and treating depression, noting that up to one-third of antidepressant prescriptions involve non-indicated use; it also introduces FDA-approved treatments, esketamine nasal spray, and brexanolone IV injection.

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.

Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.

This review discusses various extra facial esthetic indications of botulinum toxin, like neck rejuvenation and calf slimming, and reports no clinical results; essential tips for each indication are included.

This article discusses the significant impact of shame on diabetes self-management and emphasizes the need to address it in therapy, although it presents no new clinical results.

In this study conducted at Sir Ganga Ram Teaching Hospital in Pakistan, researchers found that preoperative use of finasteride significantly reduced intraoperative blood loss and shortened hospital stay for benign prostatic hyperplasia patients undergoing bipolar TURP, compared to those not receiving finasteride.

This study found that the Transdermal Delivery System efficiently delivers testosterone systemically and showed bioequivalent hormone concentrations to a known topical gel in healthy males.

This study found extensive real-world and clinical trial exposure to baricitinib across various disease states, ages, and racial populations, contributing data to its overall profile.

This study reviews current trends and the state of research on botulinum toxin in dermatology, aiming to help researchers identify key areas and explore new research directions.

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

In this study, baricitinib was found to be effective and safe for treating severe alopecia areata, with significant hair regrowth observed in many patients by the third month of therapy and continued improvement by the twelfth month, despite mostly mild adverse events.

This case report details two siblings with trichothiodystrophy, identifying reduced hair sulfur content as essential for diagnosis despite varied symptoms complicating recognition.

In this randomized, controlled, clinical trial, the researchers found that injectable botulinum toxin did not promote hair growth in men with androgenetic alopecia over 12 or 24 weeks, showing no benefit in improving hair density compared to placebo.

This study observed that men receiving dutasteride for benign prostatic hyperplasia did not show significant differences in neuropsychological assessments compared to a control group not on dutasteride.